Portal de Periódicos da CAPES

Finasteride in the Treatment of Benign Prostatic Hyperplasia. A Urodynamic Evaluation

1992; Wiley; Volume: 70; Issue: 1 Linguagem: Inglês

10.1111/j.1464-410x.1992.tb15666.x

1365-2176

Roger Kirby, JENNY BRYAN, Ian Eardley, T. J. CHRISTMAS, S. Liu, S. A. Holmes, Justin Vale, K. Shanmuganathan, Judith A. W. Webb,

Prostate Cancer Diagnosis and Treatment

Summary— A group of 69 men with bladder outflow obstruction due to benign prostatic hyperplasia (BPH) were treated in a double‐blind, placebo‐controlled study with finasteride (Proscar, MK‐906), a 5‐alpha reductase inhibitor, 5 mg or 10 mg/day or placebo for 3 months; subsequently, 20 patients received finasteride 5 mg/day for a further 9 months in an open extension study. In treated patients dihydrotestosterone declined by over 60%, remaining unchanged with placebo. Symptom scores fell significantly in all 3 groups. Mean maximum flow rates fell slightly in placebo‐treated patients but improved by 1.5 ml/s in the 10 mg group and by 3.3 ml/s in the 5 mg group. After 1 year's treatment, the reduction in symptom score and increase in flow rate were well maintained; the mean prostate volume was reduced by 14% and prostatic specific antigen declined by 28%. It was concluded that finasteride shows some efficacy in the treatment of BPH, with minimal toxicity, but 12 months of therapy or longer may be necessary to achieve maximal effect.